Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Accounts of Chemical Research
|
August 25, 2023
Exploiting Albumin as a Versatile Carrier for Cancer Theranostics
Yucen Tao, Vivianne Jakobsson, Xiaoyuan Chen, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
June 14, 2024
Engineered Antibodies as Cancer Radiotheranostics
Zhenni Wei, Bingyu Li, Xuejun Wen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 1, 2023
Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles
Richard P Baum, Xin Fan, Vivianne Jakobsson, et al.
Theranostics
|
January 3, 2024
Long-term Nephrotoxicity after PRRT: Myth or Reality
Richard P Baum, Xin Fan, Vivianne Jakobsson, et al.
Frontiers in Medicine
|
December 26, 2022
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Mengqi Shi, Vivianne Jakobsson, Lukas Greifenstein, et al.
Theranostics
|
January 2, 2024
Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
Richard P Baum, Peipei Wang, Vivianne Jakobsson, et al.
ACS Applied Materials & Interfaces
|
July 23, 2024
Targeted Radionuclide Therapy in Glioblastoma
Xiaobin Zhao, Vivianne Jakobsson, Yucen Tao, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 21, 2024
A comparison of [<sup>18</sup>F]AlF- and <sup>68</sup>Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging
Nan Liu, Qiang Wan, Xiaoming Wu, et al.
Clinical Nuclear Medicine
|
May 5, 2025
Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma
Jingjing Zhang, Deling Li, Mengqi Shi, et al.
Theranostics
|
February 24, 2025
First-in-human study of an optimized, potential kit-type, SSTR antagonist <sup>68</sup>Ga-DATA<sup>5m</sup>-LM4 in patients with metastatic neuroendocrine tumors
Jingjing Zhang, Lukas Greifenstein, Vivianne Jakobsson, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Accounts of Chemical Research
|
August 25, 2023
Exploiting Albumin as a Versatile Carrier for Cancer Theranostics
Yucen Tao, Vivianne Jakobsson, Xiaoyuan Chen, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
June 14, 2024
Engineered Antibodies as Cancer Radiotheranostics
Zhenni Wei, Bingyu Li, Xuejun Wen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 1, 2023
Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles
Richard P Baum, Xin Fan, Vivianne Jakobsson, et al.
Theranostics
|
January 3, 2024
Long-term Nephrotoxicity after PRRT: Myth or Reality
Richard P Baum, Xin Fan, Vivianne Jakobsson, et al.
Frontiers in Medicine
|
December 26, 2022
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Mengqi Shi, Vivianne Jakobsson, Lukas Greifenstein, et al.
Theranostics
|
January 2, 2024
Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
Richard P Baum, Peipei Wang, Vivianne Jakobsson, et al.
ACS Applied Materials & Interfaces
|
July 23, 2024
Targeted Radionuclide Therapy in Glioblastoma
Xiaobin Zhao, Vivianne Jakobsson, Yucen Tao, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 21, 2024
A comparison of [<sup>18</sup>F]AlF- and <sup>68</sup>Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging
Nan Liu, Qiang Wan, Xiaoming Wu, et al.
Clinical Nuclear Medicine
|
May 5, 2025
Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma
Jingjing Zhang, Deling Li, Mengqi Shi, et al.
Theranostics
|
February 24, 2025
First-in-human study of an optimized, potential kit-type, SSTR antagonist <sup>68</sup>Ga-DATA<sup>5m</sup>-LM4 in patients with metastatic neuroendocrine tumors
Jingjing Zhang, Lukas Greifenstein, Vivianne Jakobsson, et al.
Page
of 2